BridgeBio Pharma, Inc. Detailed Financials
Full historical quarterly statements
| Metric | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 194.5M | 154.2M | 120.7M | 110.6M | 116.6M | 5.9M | 2.7M | 2.2M |
| Cost of Goods Sold | 10.4M | 15.4M | 6.6M | 3.7M | 2.6M | 2.1M | 598K | 598K |
| Gross Profit | 184.1M | 138.8M | 114.1M | 106.9M | 114.0M | 3.8M | 2.1M | 1.6M |
| R&D Expenses | 126.6M | 142.0M | 112.9M | 111.2M | 111.4M | 130.3M | 120.4M | 114.7M |
| Operating Expenses | 290.0M | 324.0M | 259.3M | 241.2M | 218.4M | 229.8M | 193.9M | 177.1M |
| Operating Income | -106.0M | -185.2M | -145.2M | -134.3M | -104.4M | -226.0M | -191.8M | -175.5M |
| Other Income / Gains | -60.6M | -12.0M | -41.3M | -47.4M | -65.2M | -40.2M | 27.5M | 100.0M |
| Net Income | -164.0M | -197.2M | -182.7M | -181.9M | -167.4M | -265.1M | -162.0M | -73.5M |
| EPS (Diluted) | -0.84 | -1.00 | -0.96 | -0.95 | -0.88 | -1.40 | -0.86 | -0.39 |
| Reported Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Gross Profit Ratio | 0.946 | 0.90 | 0.946 | 0.967 | 0.977 | 0.646 | 0.781 | 0.724 |
| General And Administrative Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling And Marketing Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling General And Administrative Expenses | 163.9M | 182.0M | 137.6M | 129.2M | 106.4M | 94.8M | 68.8M | 59.5M |
| Other Expenses | -486K | 0 | 8.8M | 805K | 570K | 4.7M | 4.6M | 2.9M |
| Cost And Expenses | 300.5M | 339.4M | 265.9M | 244.8M | 221.0M | 231.9M | 194.5M | 177.7M |
| Interest Income | 6.2M | 4.3M | 6.2M | 3.9M | 5.4M | 4.7M | 3.3M | 5.2M |
| Interest Expense | 52.8M | 12.0M | 11.7M | 37.6M | 42.1M | 29.8M | 23.1M | 22.9M |
| Depreciation And Amortization | 1.2M | 5.0M | 1.4M | 1.3M | 1.3M | 1.4M | 1.5M | 1.6M |
| Ebitda | -104.8M | -180.2M | -173.3M | -142.7M | -126.2M | -235.0M | -139.7M | -51.0M |
| Ebitdaratio | -0.539 | -1.169 | -1.436 | -1.291 | -1.082 | -39.961 | -51.118 | -23.539 |
| Operating Income Ratio | -0.545 | -1.201 | -1.203 | -1.214 | -0.895 | -38.427 | -70.187 | -80.968 |
| Income Before Tax | -166.6M | -197.2M | -186.5M | -181.7M | -169.6M | -266.2M | -164.3M | -75.5M |
| Income Before Tax Ratio | -0.856 | -1.279 | -1.545 | -1.643 | -1.454 | -45.263 | -60.122 | -34.845 |
| Income Tax Expense | 0 | 0 | -1.5M | 2.1M | 0 | 1.2M | 0 | 0 |
| Net Income Ratio | -0.843 | -1.279 | -1.514 | -1.645 | -1.435 | -45.061 | -59.312 | -33.882 |
| Epsdiluted | -0.84 | -1.00 | -0.96 | -0.95 | -0.88 | -1.40 | -0.86 | -0.39 |
| Weighted Average Shs Out | 194.8M | 197.2M | 190.5M | 190.5M | 190.1M | 189.4M | 188.5M | 187.6M |
| Weighted Average Shs Out Dil | 194.8M | 197.2M | 190.5M | 190.5M | 190.1M | 189.4M | 188.5M | 187.6M |